Hostname: page-component-78c5997874-ndw9j Total loading time: 0 Render date: 2024-11-09T05:58:49.473Z Has data issue: false hasContentIssue false
  • English
  • Français

Sex Steroid and Growth Factor Profile of a Meningioma Associated with Pregnancy

Published online by Cambridge University Press:  02 December 2014

Justin S. Smith ,
Alfredo Quiñones-Hinojosa ,
Miranda Harmon-Smith ,
Andrew W. Bollen  and
Michael W. McDermott
Justin S. Smith
Affiliation:
Department of Neurological Surgery, University of California at San Francisco, San Francisco, California USA
Alfredo Quiñones-Hinojosa
Affiliation:
Department of Neurological Surgery, University of California at San Francisco, San Francisco, California USA
Miranda Harmon-Smith
Affiliation:
Department of Neurological Surgery, University of California at San Francisco, San Francisco, California USA
Andrew W. Bollen
Affiliation:
Department of Pathology, University of California at San Francisco, San Francisco, California USA
Michael W. McDermott
Affiliation:
Department of Neurological Surgery, University of California at San Francisco, San Francisco, California USA
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

Increased growth of meningiomas during pregnancy as well as postpartum clinical regression of symptoms have been reported but remain poorly understood. A better understanding of the factors that contribute to these observations, including potential factors associated with pregnancy, could enable design of more effective adjuvant therapies.

Methods:

We describe the presentation of a meningioma during the immediate postpartum period. Serial imaging demonstrated subsequent rapid decrease in size of the tumour prior to any intervention. The lesion was resected, and the tissue was subjected to immunostaining for gene products associated with pregnancy, including estrogen receptor (ER), progesterone receptor (PR), platelet-derived growth factor receptor B (PDGFRB), fibroblastic growth factor receptor 2 (FGFR-2), epidermal growth factor receptor (EGFR) and human placental lactogen (hPL).

Results:

The lesion proved to be an atypical fibroblastic meningioma grade II (WHO). Immunostaining demonstrated significant staining for PR, PDGFRB, and FGFR-2. No specific staining for ER, EGFR, or hPL was identified.

Conclusion:

Although clinical regression of meningioma following pregnancy is well-recognized, imaging data are much less abundant. This report provides clear clinical and imaging documentation of a meningioma associated with pregnancy. In addition, the growth factor profile of this tumour suggests the importance of PR, PDGFRB, and FGFR-2 as potential therapeutic targets.

Résumé:

RÉSUMÉ:Introduction:

Une augmentation de la croissance de méningiomes pendant la grossesse ainsi Qu’une régression clinique post–partum des symptômes ont déjà été rapportés. Cependant la compréhension de ces phénomènes demeure limitée. Une meilleure compréhension des facteurs qui contribuent à ces observations, particulièrement de facteurs pouvant être associés à la grossesse, pourrait aider au développement de meilleurs traitements adjuvants.

Méthodes:

Nous décrivons l’évolution d’un méningiome pendant la période immédiate du post–partum. L’imagerie en série a montré une diminution rapide de la taille de la tumeur avant toute intervention. La lésion a été enlevée et soumise à un immunomarquage pour des substances associées à la grossesse, dont les récepteurs des oestrogènes (RO), le récepteur de la progestérone (RP), le récepteur B du facteur de croissance dérivé des plaquettes (PDGFRB), le récepteur 2 du facteur de croissance fibroblastique FGFR–2), le récepteur du facteur de croissance épidermique (EGFR) et l’hormone lactogène placentaire humaine (hLP).

Résultats:

La lésion a été classifiée comme un méningiome fibroblastique de grade II (OSM). À l’immunomarquage, on a observé une coloration importante pour le RP, le PDGFRB et le FGFR–2 et aucune coloration pour le RO, l’EGFR ou le hLP.

Conclusion:

Bien que la régression clinique des méningiomes après la grossesse soit bien connue, il y a peu de données sur son imagerie. Cet article présente le tableau clinique et l’imagerie d’un méningiome associé à une grossesse. De plus, le profil des facteurs de croissance de cette tumeur suggère que le RP, le PDGFRB et le FGFR– 2 pourraient être des cibles thérapeutiques importantes.

Type
Case Report
Information
Canadian Journal of Neurological Sciences , Volume 32 , Issue 1 , February 2005 , pp. 122 - 127
Copyright
Copyright © The Canadian Journal of Neurological 2014

References

1. Longstreth, WT, Dennis, LK, McGuire, VM, Drangsholt, MT, Koepsell, TD. Epidemiology of intracranial meningioma. Cancer 1993; 72: 639–648.Google Scholar
2. Stafford, SL, Perry, A, Suman, VJ, et al. Primarily resectedmeningiomas: outcome and prognostic factors in 581 MayoClinic patients, 1978 through 1988. Mayo Clin Proc 1998; 73: 936–942.CrossRefGoogle Scholar
3. Bickerstaff, ER, Small, JM, Guest, IA. The relapsing course of certainmeningiomas in relation to pregnancy and menstruation. J Neurol Neurosurg Psychiatry 1958; 21: 89–91.Google Scholar
4. Black, PML. Hormone, radiosurgery and virtual reality: new aspectsof meningioma management. Can J Neurol Sci 1997; 24: 302–306.Google Scholar
5. Benzel, EC, Gelder, FB. Correlation between sex hormone bindingand peritumoural edema in intracranial meingiomas. Neurosurgery 1988; 23: 169–174.Google Scholar
6. DeGrood, RM, Beemer, WH, Fenner, DE, Compton, AA. A largemeningioma presenting as a neurologic emergency in latepregnancy. Obstet Gynecol 1987; 69: 439–440.Google Scholar
7. Kempers, RD, Miller, RH. Management of pregnancy associatedwith brain tumours. Am J Obstet Gynecol 1963; 87: 858–864.CrossRefGoogle Scholar
8. Schlehofer, B, Blettner, M, Wahrendorf, J. Association between braintumours and menopausal status. J Natl Cancer Inst 1992; 84: 1346–1349.Google Scholar
9. Helseth, A, Mork, SJ, Glattre, E. Neoplasms of the central nervoussystem in Norway. V, meningioma and cancer of other sites. An analysis of the occurrence of multiple primary neoplasms in meningioma patients in Norway from 1955 through 1986. APMIS 1989; 97: 738–744.CrossRefGoogle Scholar
10. Schoenberg, BS, Christine, BW, Whisant, JP. Nervous systemneoplasms and the primary malignancies of other sites. The unique association between meningiomas and breast cancer. Neurology 1975; 28: 705–712.Google Scholar
11. Brandis, A, Mirazi, S, Tatagiba, M, et al. Immunohistochemicaldetection of female sex hormone receptors in meningiomas: correlation with clinical and histological features. Neurosurgery 1993; 33: 212–217.Google Scholar
12. Carroll, RS, Zhang, J, Dashner, K, Black, PML. Progesterone andglucocorticoid activation in meningiomas. Neurosurgery 1995; 37: 92–97.Google Scholar
13. Fewings, PE, Battersby, RD, Timperley, WR. Long-term follow up ofprogesterone receptor status in benign meningioma: a prognostic indicator of recurrence? J Neurosurg 2000; 92: 401–405.Google Scholar
14. Hsu, DW, Efird, JT, Hedley-Whyte, ET. Progesterone and estrogenreceptors in meningiomas: prognostic considerations. J Neurosurg 1997; 86: 113–120.Google Scholar
15. Perry, A, Cai, DX, Scheithauer, BW, et al. Merlin, DAL-1, andprogesterone receptor expression in clinicopathologic subsets of meningioma: a correlative immunohistochemical study of 175cases. J Neuropathol Exp Neurol 2000; 59: 872–879.Google Scholar
16. Tilzer, LL, Plapp, FV, Evans, JP, Stone, D, Alward, K. Steroid receptorproteins in human meningiomas. Cancer 1982; 49: 633–636.Google Scholar
17. Verheijen, FM, Sprong, M, Jacobs, GH, et al. Progesterone receptorisoform expression in human meningiomas. Eur J Cancer 2001; 37: 1488–1495.Google Scholar
18. Roelvink, NCA, Kamphorst, W, van Alphen, HAM, Rao, BR. Pregnancy-related primary brain and spinal tumours. Arch Neurol 1987; 44: 209–215.CrossRefGoogle Scholar
19. Philippon, J, Foncin, JF, Grob, R, et al. Cerebral edema associatedwith meningiomas: Possible role of a secretory-excretory phenomenon. Neurosurgery 1984;14: 295–301.Google Scholar
20. Isla, A, Alvarez, F, Gonzalez, A, et al. Brain tumour and pregnancy. Obstet Gynecol 1997; 89: 19–23.Google Scholar
21. Giannini, A, Bricchi, M. Posterior fossa surgery in the sitting positionin a pregnant patient with cerebellopontine angle meningioma. Br JAnaesth 1999; 82: 941–944.Google Scholar
22. Goldberg, M, Rappaport, ZH. Neurosurgical, obstetric and endocrineaspects of meningioma during pregnancy. Isr J Med Sci 1987; 23: 825–828.Google Scholar
23. Ismail, K, Coakham, HB, Walters, FJ. Intracranial meningioma withprogesterone positive receptors presenting in late pregnancy. Eur JAnaesthesiol 1998; 15: 106–109.Google Scholar
24. Old, SE, Burnet, NG, Macfarlane, R, O’Donovan, DG, Langmack, K. Post-partum retreatment with iridium-192 wire brachytherapy for meningioma recurring in pregnancy. Clin Oncol 2001; 13: 114–116.Google Scholar
25. Pliskow, S, Herbst, SJ, Saiontz, HA, Cove, H, Ackerman, RT. Intracranial meningioma with positive progesterone receptors: a case report. J Reprod Med 1995; 40: 154–156.Google ScholarPubMed
26. Saitoh, Y, Oku, Y, Izumoto, S, Go, J. Rapid growth of a meningiomaduring pregnancy: relationship with estrogen and progesterone receptors. Neurol Med Chir (Tokyo) 1989; 29: 440–443.Google Scholar
27. Sanson, M, Cornu, P. Biology of meningiomas. Acta Neurochir (Wien) 2000; 142: 493–505.Google Scholar
28. Carroll, RS, Glowacka, D, Dashner, K, Black, PM. Progesteronereceptor expression in meningiomas. Cancer Res 1993; 53: 1312–1326.Google Scholar
29. Gospodarowicz, D, Ferrara, N, Schweigerer, L, Neufeld, G. Structuralcharacterization and biological functions of fibroblast growth-factor. Endocr Rev 1987; 8: 95–114.Google Scholar
30. Gross, JL, Morrison, RS, Eidsvoog, K, et al. Basic fibroblast growth-factor – a potential autocrine regulator of human glioma cell-growth. J Neurosci Res 1990; 27: 689–696.Google Scholar
31. Lamszus, K, Lengler, U, Dchmidt, NO, et al. Vascular endothelialgrowth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor in human meningiomas and their relation to angiogenesis and malignancy. Neurosurgery 2000; 46: 938–948.Google Scholar
32. Takahashi, JA, Suzui, H, Yasuda, Y, et al. Gene expression offibroblast growth factor receptors in the tissues of human gliomas and meningiomas. Biochem Biophys Res Commun 1991; 177: 1–7.Google Scholar
33. Takahashi, JA, Mori, H, Fukumoto, M, et al. Gene expression offibroblast growth factors in human gliomas and meningiomas: demonstration of cellular or basic fibroblast growth factor mRNA and peptide in tumour tissue. Proc Natl Acad Sci USA 1990; 87: 5710.Google Scholar
34. Black, PML, Carroll, R, Glowacka, D, Riley, K, Dashner, K. Platelet-derived growth factor expression and stimulation in human meningiomas. J Neurosurg 1994; 81: 388–393.CrossRefGoogle ScholarPubMed
35. Maxwell, M, Galanopoulos, T, Hedley-Whyte, ET, Black, PML, Antoniades, HN. Human meningiomas co-express platelet-derived growth factor (PDGF) and PDGF-receptor genes and protein products. Int J Cancer 1990; 46: 16–21.Google Scholar
36. Yang, SY, Xu, GM. Expression of PDGF and its receptor as well astheir relationship to proliferating activity and apoptosis of meningiomas in human meningiomas. J Clin Neurosci 2000; 8: 49–53.Google Scholar
37. Boyle-Walsh, E, Shenkin, A, White, MC, Fraser, WD. Effect ofglycoprotein and protein hormones on human meningioma cell proliferation in vitro. J Endocrinol 1995; 145: 155–161.Google Scholar
38. Carroll, RS, Black, PML, Zhang, J, et al. Expression and activation ofepidermal growth factor receptors in meningiomas. J Neurosurg 1997; 87: 315–323.Google Scholar
39. Jones, NR, Rossi, ML, Gregoriou, M, Hughes, JT. Epidermal growthfactor receptor expression in 72 meningiomas. Cancer 1990; 66: 152–155.Google Scholar